Halozyme Therapeutics (HALO) FY2015 results: revenue $135 million, up 79.3% on the year
Halozyme Therapeutics, Inc. (HALO) reported revenue of $135 million for fiscal 2015, the year ended 31 December 2015, up 79.3% on the year before. Net income was -$32 million, and diluted earnings per share $-0.25. The figures are the company's own, from the 10-K it filed with the SEC on 29 February 2016.
Revenue
$135 million
+79.3% on the year
FY2009FY2015
Operating margin
-20.3%
-83.7% a year earlier
FY2009FY2015
Net income
-$32 million
FY2009FY2015
Diluted EPS
-$0.25
FY2009FY2015
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Revenue
135
75.3
54.8
+79.3%
Cost of revenue
29.2
22.7
6.2
+28.7%
Gross profit
106
52.6
48.6
+101.2%
Gross margin
78.3%
69.8%
88.6%
Research and development
93.2
79.7
96.6
+17.0%
Selling, general and administrative
40.0
35.9
32.3
+11.4%
Operating income
-27.5
-63.0
-80.4
Operating margin
-20.3%
-83.7%
-146.8%
Interest expense
5.2
5.6
3.3
-6.8%
Pre-tax income
-32.2
-68.4
n/a
Income tax
0.0
0.0
n/a
Net income
-32.2
-68.4
-83.5
Net margin
-23.9%
-90.8%
-152.3%
Diluted EPS
-$0.25
-$0.56
-$0.74
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Operating cash flow
-37.1
-47.5
-49.3
Capital expenditure
2.4
1.4
2.3
+72.5%
Free cash flow
-39.4
-48.9
-51.6
Free cash flow margin
-29.2%
-64.9%
-94.2%
Cash from investing
5.9
-33.0
-47.9
Cash from financing
13.1
115
25.1
-88.6%
Depreciation and amortisation
1.7
1.8
1.2
-4.8%
Share-based compensation
20.8
15.3
9.5
+36.4%
Diluted shares, weighted
127m
n/a
n/a
Shares outstanding at period end
128m
126m
115m
+1.9%
Balance sheet
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Shareholders' equity
43.0
41.4
-20.0
+4.0%
Debt
49.8
49.9
49.8
-0.1%
Other liabilities
89.0
74.8
72.0
+19.0%
Total liabilities and equity
182
166
102
+9.5%
Fixed assets
3.9
3.0
3.4
+33.6%
Investments
65.0
74.2
44.1
-12.4%
Cash and equivalents
43.3
61.4
27.4
-29.5%
Receivables
32.4
9.1
9.1
+254.2%
Inventory
9.5
6.4
6.2
+48.1%
Other assets
27.6
11.8
11.6
+133.0%
Total assets
182
166
102
+9.5%
10-K for the year ended 31 December 2015, filed 29 February 2016: the filing.